STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease — StellaPhase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.
Trial locations(27 sites)
Austria
Vorarlberger Krankenhaus-Betriebsgesellschaft, Feldkirch Medizinische Universitaet Innsbruck, Innsbruck Germany
Universitaetsklinikum Aachen AöR, Aachen Charite Universitaetsmedizin Berlin KöR, Berlin Universitätsklinikum Köln, Cologne Last updated February 2026